Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corporation (OCX) is a pioneering precision diagnostics company dedicated to the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics aimed at facilitating clinical decision-making in the early detection of cancer. The company focuses on molecular tests that address high unmet needs in the diagnosis of lung, breast, and bladder cancers, conditions where current diagnostic standards are often ambiguous, costly, and invasive. Oncocyte's tests are developed based on a proprietary set of biomarkers, designed to differentiate between benign and malignant nodules or masses.
Oncocyte’s flagship products include:
- DetermaIO™: A gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
- DetermaCNI™: A blood-based monitoring tool for therapeutic efficacy in cancer patients.
- VitaGraft™: A blood-based solid organ transplantation monitoring test.
- GraftAssure™: A research-use-only monitoring test for solid organ transplantation.
The company has made significant strides in expanding its diagnostic capabilities and achieving key regulatory and commercial milestones. In 2023, Oncocyte secured reimbursement for VitaGraft™ Kidney, manufactured the initial lots of GraftAssure RUO, and entered a strategic partnership with Bio-Rad Laboratories to commercialize GraftAssure and develop VitaGraft Kidney IVD. This partnership, along with a successful $15.8 million private placement offering, positions Oncocyte well to meet its critical commercial and regulatory goals.
Oncocyte continues to be supported by strong core investors and aims to provide clarity and confidence to physicians and their patients through its groundbreaking diagnostic tests. For more information, visit www.oncocyte.com.
Oncocyte Corporation (Nasdaq: OCX) announced participation in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference on September 14, 2021. Management will engage in one-on-one and group investor meetings aimed at presenting the company's precision diagnostics and monitoring capabilities for cancer. Oncocyte focuses on improving patient outcomes through proprietary tests like DetermaRx™ and DetermaIO™, which aid in early detection and treatment decisions in oncology. Interested investors can contact Lake Street Capital Markets for meeting arrangements.
Oncocyte Corporation (Nasdaq: OCX) has announced the launch of the Predictive Assay for Decision Making in Adjuvant Therapy (PADMA) Registry aimed at enrolling over 1,000 patients with early-stage lung cancer across 25 hospitals in the U.S. The registry seeks to collect data on the impact of biomarker adoption and precision medicine using their DetermaRx™ test, improving treatment decisions for patients post-surgery. The PADMA Registry reflects Oncocyte's commitment to enhancing patient outcomes through precise diagnostics in cancer treatment.
Oncocyte Corporation (Nasdaq: OCX) reported a 23% rise in sample volume for DetermaRx in Q2 2021. Financial results showed revenues of $2.03 million, exceeding estimates, largely due to DetermaRx's growth. The company plans to launch three new products in Q4, including DetermaIO, which demonstrates potential as a predictive biomarker for immunotherapy. The acquisition of Chronix enables entry into blood-based monitoring markets. However, Q2 operational losses widened to $13.6 million, with a net loss of $10.5 million, or ($0.12) per share.
Oncocyte Corporation (Nasdaq: OCX) announced participation in two key investor conferences. The UBS Genomics 2.0 & MedTech Innovations Summit will take place on August 12, 2021, at Montage Laguna Beach, featuring 1x1 and group meetings. Following this, the 6th Annual Needham Virtual Med Tech & Diagnostics Conference is scheduled for August 17, 2021, also with 1x1 and group formats. Oncocyte aims to enhance cancer diagnosis and treatment through its precision diagnostics and proprietary tests, including DetermaRx and DetermaIO, which are designed to improve patient outcomes.
Oncocyte Corporation (Nasdaq: OCX) announced it will release its financial results for Q2 2021 after market close on August 10, 2021. The company will host a conference call at 4:30 PM ET to discuss the results and recent developments. Oncocyte focuses on precision diagnostics for cancer, aiming to enhance patient outcomes through its proprietary tests like DetermaRx and DetermaIO. The company emphasizes its commitment to improving cancer care and accelerating diagnoses. Forward-looking statements highlight risks, including COVID-19 impacts and uncertainties in clinical development.
Oncocyte Corporation (NYSE American: OCX) has entered a strategic collaboration with Echelon Diagnostics, Inc. to develop analytical software aimed at enhancing the scalability and commercialization of Oncocyte's diagnostic tests. This partnership is expected to improve cancer diagnosis and treatment, ultimately leading to better patient outcomes and reduced healthcare costs. Echelon's expertise in informatics and diagnostic solutions will support Oncocyte's mission to provide actionable insights in cancer care, reflecting a commitment to innovation and quality in genomics.
Oncocyte Corporation (Nasdaq: OCX) has partnered with Gruppo Oncologico del Nord-Ovest (GONO Foundation) to evaluate the DetermaIO test for predicting immunotherapy response in metastatic colorectal cancer (mCRC). This marks the test's assessment in a fifth tumor type, following its previous successes in lung, breast, bladder, and renal cancers. The collaboration aims to identify mCRC patients who may benefit from immunotherapy despite lacking the microsatellite instability biomarker. The GONO Foundation conducts clinical trials in oncology, making it a suitable partner for this initiative.
Oncocyte Corporation (NASDAQ: OCX) has announced the addition of the Therascreen RGQ KRAS test in its Nashville CLIA lab, enhancing its diagnostic offerings for lung cancer. This follows a partnership with QIAGEN to support Amgen’s LUMAKRAS therapy for KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC). As a result, Oncocyte aims to consolidate its position as a key player in cancer diagnostics, providing essential information for treatment decisions. The new test addresses an unmet clinical need, as KRAS G12C mutations represent 25% of all NSCLC cases.
Oncocyte Corporation (NASDAQ: OCX) reported Q1 2021 revenues of $1.12 million, exceeding analyst estimates, driven by growth in DetermaRx and Pharma Services. The company highlighted strong data supporting the pan-cancer utility of DetermaIO, with pilot projects secured from three biopharma partners. The acquisition of Chronix Biomedical opens opportunities in the blood-based therapy monitoring market. Operating losses increased to $11.4 million, while cash used in operations was approximately $9.8 million. The anticipated launch of DetermaIO and other products may drive significant revenue growth in the next 18-24 months.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
What does Oncocyte Corporation specialize in?
What types of cancer does Oncocyte's diagnostics target?
What are some of Oncocyte's key products?
How does Oncocyte's DetermaIO™ test work?
What recent achievements has Oncocyte made?
Who are some of Oncocyte's partners?
What is the purpose of Oncocyte's VitaGraft™ test?
What is GraftAssure™ used for?
How does Oncocyte support its operations financially?
Where can I find more information about Oncocyte Corporation?
